IP Library Granted Patent US 9,370,470
Granted Patent B2
US 9,370,470 · App. 14/227,365 · Granted Jun 21, 2016

Injectable alloplastic implants and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,370,470
App. No.
14/227,365
Granted
Jun 21, 2016
Kind
B2
Abstract

Described herein are injectable alloplastic implant compositions that are particularly useful for soft tissue defect augmentation. The compositions include microparticles, such as polymethylmethacrylate particles, and collagen as a suspending agent, wherein the collagen contains a reduced amount of low molecular weight gelatine compared to high molecular weight collagen. By controlling the molecular weight of the collagen in the compositions, the injectability, stability, and antigenicity of the alloplastic implant compositions can be improved.

Claims (12)

1. An alloplastic implant composition comprising

microparticles having a diameter of about 5 to about 400 μm suspended in

an aqueous suspending agent, wherein the aqueous suspending agent comprises denatured atelocollagen, wherein the denatured atelocollagen has less than 10 wt % of the total weight as components of weight average molecular weight (Mw) 100,000 Daltons or lower, and greater than 70 wt % components of weight average molecular weight 100 kDa to 258 kDa,

wherein the polydispersity of the denatured atelocollagen expressed as Mw/Mn is 1.0 to 1.6, wherein Mw is weight average molecular weight and Mn is number average molecular weight.

2. The alloplastic implant composition of claim 1 , wherein the denatured atelocollagen is prepared from bovine or porcine collagen.

3. The alloplastic implant composition of claim 1 , wherein the pH of the aqueous suspending agent is 6.0 to 8.0 and the concentration of denatured atelocollagen in the aqueous suspending agent is 0.5 to 15 wt %.

4. The alloplastic implant composition of claim 1 , wherein the microparticles have a diameter of about 10 to about 200 μm.

5. The alloplastic implant composition of claim 1 , wherein the microparticles comprise a polymer or copolymer comprising a methacrylate monomer.

6. The alloplastic implant composition of claim 5 , wherein the polymer or copolymer is polymethylmethacrylate.

7. The alloplastic implant composition of claim 1 , wherein the composition is injectable through a 20 to 30 gauge needle.

8. The alloplastic implant composition of claim 1 , further comprising an anesthetic.

9. The alloplastic implant composition of claim 1 , wherein the suspension is stable for at least 30 days at a temperature of 20-25° C.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Oct 22, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: SUNEVA MEDICAL, INC.
Reel/Frame 068968/0598 →
SECURITY INTEREST Recorded Aug 24, 2021
From: SUNEVA MEDICAL, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
Reel/Frame 057277/0460 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2016
From: MASI, LOUIS
To: SUNEVA MEDICAL, INC.
Reel/Frame 038995/0732 →
CHANGE OF ASSIGNEE ADDRESS Recorded Jun 23, 2016
From: SUNEVA MEDICAL, INC.
To: SUNEVA MEDICAL, INC.
Reel/Frame 039140/0443 →